Cannabis-based medicines and medical cannabis for patients with neuropathic pain and other pain disorders : Nationwide register-based pharmacoepidemiologic comparison with propensity score matched controls
© 2021 European Pain Federation - EFIC®..
BACKGROUND: Neuropathic pain and other pain disorders have received attention as potential indications for use of cannabis-based medicines or medical cannabis (CBM/MC). Evidence regarding the efficacy and safety of CBM/MC for pain disorders is, however, insufficient. Denmark introduced a pilot programme of medical cannabis in January 2018. We aimed to evaluate efficacy, safety, and non-specific effects of CBM/MC used under the pilot programme compared with controls.
METHODS: We conducted a nationwide register-based cohort study in Denmark, identifying all individuals redeeming at least one prescription for CBM/MC for either neuropathic pain (n = 1817) or other and unspecified pain disorders (n = 924), and to match one control to each case using propensity score matching.
RESULTS: Among both patient groups, users of THC used more opioids during follow-up than controls. Among patients with neuropathic pain, however, users of either CBD, THC, or combined CBD + THC used less gabapentin than controls. Users of all three classes of CBM/MC were hospitalized fewer days than controls among neuropathic-pain patients but not among patients with other or unspecified pain disorders.
CONCLUSIONS: CBM/MC were generally safe and even displayed some positive effects among patients with neuropathic pain. We conclude that CBM/MC are safe and possibly efficacious for patients with neuropathic pain but not patients with other pain disorders.
SIGNIFICANCE: Patients with neuropathic pain may benefit from treatment with cannabis-based medicines or medical cannabis (CBM/MC), particularly in terms of reduced use of gabapentin and fewer days admitted to hospitals, compared with propensity score matched controls. CBM/MC did not, however, reduce the use of opioids. We did not find evidence that CBM/MC were effective for patients with other pain disorders.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
European journal of pain (London, England) - 26(2022), 2 vom: 13. Feb., Seite 480-491 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hjorthøj, Carsten [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 04.03.2022 Date Revised 04.03.2022 published: Print-Electronic CommentIn: Eur J Pain. 2022 Jan;26(1):3-4. - PMID 34743399 Citation Status MEDLINE |
|---|
| doi: |
10.1002/ejp.1874 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331651297 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331651297 | ||
| 003 | DE-627 | ||
| 005 | 20231225213928.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ejp.1874 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1105.xml |
| 035 | |a (DE-627)NLM331651297 | ||
| 035 | |a (NLM)34624164 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hjorthøj, Carsten |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cannabis-based medicines and medical cannabis for patients with neuropathic pain and other pain disorders |b Nationwide register-based pharmacoepidemiologic comparison with propensity score matched controls |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.03.2022 | ||
| 500 | |a Date Revised 04.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Eur J Pain. 2022 Jan;26(1):3-4. - PMID 34743399 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 European Pain Federation - EFIC®. | ||
| 520 | |a BACKGROUND: Neuropathic pain and other pain disorders have received attention as potential indications for use of cannabis-based medicines or medical cannabis (CBM/MC). Evidence regarding the efficacy and safety of CBM/MC for pain disorders is, however, insufficient. Denmark introduced a pilot programme of medical cannabis in January 2018. We aimed to evaluate efficacy, safety, and non-specific effects of CBM/MC used under the pilot programme compared with controls | ||
| 520 | |a METHODS: We conducted a nationwide register-based cohort study in Denmark, identifying all individuals redeeming at least one prescription for CBM/MC for either neuropathic pain (n = 1817) or other and unspecified pain disorders (n = 924), and to match one control to each case using propensity score matching | ||
| 520 | |a RESULTS: Among both patient groups, users of THC used more opioids during follow-up than controls. Among patients with neuropathic pain, however, users of either CBD, THC, or combined CBD + THC used less gabapentin than controls. Users of all three classes of CBM/MC were hospitalized fewer days than controls among neuropathic-pain patients but not among patients with other or unspecified pain disorders | ||
| 520 | |a CONCLUSIONS: CBM/MC were generally safe and even displayed some positive effects among patients with neuropathic pain. We conclude that CBM/MC are safe and possibly efficacious for patients with neuropathic pain but not patients with other pain disorders | ||
| 520 | |a SIGNIFICANCE: Patients with neuropathic pain may benefit from treatment with cannabis-based medicines or medical cannabis (CBM/MC), particularly in terms of reduced use of gabapentin and fewer days admitted to hospitals, compared with propensity score matched controls. CBM/MC did not, however, reduce the use of opioids. We did not find evidence that CBM/MC were effective for patients with other pain disorders | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Medical Marijuana |2 NLM | |
| 700 | 1 | |a La Cour, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Nordentoft, Merete |e verfasserin |4 aut | |
| 700 | 1 | |a Posselt, Christine Merrild |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of pain (London, England) |d 1997 |g 26(2022), 2 vom: 13. Feb., Seite 480-491 |w (DE-627)NLM097398519 |x 1532-2149 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2022 |g number:2 |g day:13 |g month:02 |g pages:480-491 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ejp.1874 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2022 |e 2 |b 13 |c 02 |h 480-491 | ||